Association of glycosylated hemoglobin and outcomes in patients with COVID-19 and pre-existing type 2 diabetes

Zhang, Nie; Yun, Ruiyuan; Liu, Lin; Yang, Liu

doi:10.1097/md.0000000000023392

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large body of evidence indicates that statins improve cardiovascular outcomes through lipid-lowering and non-lipidlowering effects [59,60]. Prior studies have also shown improved outcomes in patients taking indicated drug therapy for hypertension [61] and diabetes mellitus [62]. Hence, the observed reduced mortality with statins in COVID-19 could be explained at least in part through their favorable effects on the cardiovascular system.…”

Section: Mechanismsmentioning

confidence: 99%

Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis

Yetmar

Chesdachai

Kashour

et al. 2021

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background Statins up-regulate angiotensin converting enzyme-2, the receptor of SARS-CoV-2, while also exhibiting pleiotropic antiviral, antithrombotic and anti-inflammatory properties. Uncertainties exist about their effect on the course of SARS-CoV-2 infection. Objectives We sought to systematically review the literature and perform a meta-analysis to examine the association between prior statins use and outcomes of patients with COVID-19. Methods We searched Ovid MEDLINE, Web of Science, Scopus, and the preprint server MedRxiv from inception to December 2020. We assessed the quality of eligible studies with the Newcastle-Ottawa quality scale. We pooled adjusted risk ratios (aRR) of the association between prior statins use and outcomes of patients with COVID-19 using the DerSimonian-Laird random effects model and assessed heterogeneity using the I 2-index. Results Overall, 19 (16 cohorts and 3 case-control) studies were eligible, with a total of 395,513 patients. Sixteen of 19 studies had low- or moderate-risk of bias. Among 109,080 patients enrolled in 13 separate studies, prior statins use was associated with a lower risk of mortality, (pooled aRR 0.65 (95% CI 0.56-0.77, I 2 = 84.1%) and a reduced risk of severe COVID-19 was also observed in 48,110 patients enrolled in 9 studies, (pooled aRR of 0.73 (95% CI 0.57-0.94, I 2 = 82.8%), with no evidence of publication bias. Conclusions Cumulative evidence suggests that prior statins use is associated with lower risks of mortality or severe disease in patients with COVID-19. These data support the continued use of statins medications in patients with an indication for lipid-lowering therapy during the COVID-19 pandemic.

show abstract

Section: Mechanismsmentioning

confidence: 99%

Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis

Yetmar

Chesdachai

Kashour

et al. 2021

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…A prior study indicated that glycemic control correlated with outcomes in COVID. 37 It would follow that diabetic medications act both as a marker of illness and a marker for higher likelihood of controlled illness. Thus, diabetes medications may correlate with both positive and negative effects.…”

Section: Discussionmentioning

confidence: 99%

Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19

Yetmar

Challener

Tleyjeh

et al. 2021

Mayo Clinic Proceedings: Innovations, Quality & Outcomes

View full text Add to dashboard Cite

Objective To determine the association between chronic statin use and mortality in patients hospitalized with COVID-19. Patients and Methods We identified a retrospective cohort of patients requiring admission at the Mayo Clinic using our enterprise-wide COVID-19 registry from March 1 st , 2020, through September 30 th , 2020. Available information included age, gender, use of statins, medical comorbidities, and 30-day mortality. We estimated the association of statins with 30-day mortality using odds ratios (OR) and 95% confidence intervals (CI) from logistic regression modeling. Results 1295 patients between the ages of 30 and 80 tested positive for COVID-19 and required admission during the study period, of whom 500 (38.6%) were taking statins at admission. Patients taking statins were older and more likely to have diabetes mellitus or congestive heart failure. Within 30 days of diagnosis, 59 (4.6%) died. In multivariable analysis, statin users did not have statistically different odds of death within 30 days with OR of 1.14 (95% CI: 0.64-2.03, P=.67) compared to non-users. Conclusions Patients with COVID-19 taking statins had similar 30-day mortality to those not taking statins, after adjusting for relevant covariates. Although this is partly influenced by a higher prevalence of risk factors for more severe COVID-19 presentation not entirely adjusted for by the Charlson Comorbidity Index, these data would not support statins as a likely therapeutic intervention for COVID-19 in the hospital setting.

show abstract

“…Various studies show hyperglycemia, caused by inadequate glycemic control, has been identified as a risk of COVID-19 development and poor survival [28] . In one large study carried out on 7000 individuals with nCOVID-19 in Wuhan, China, among a group with nCOVID-19 and T2DM, patients with good glycemic control reported a significant decrease in overall comorbidities and all-cause mortalities compared to those with poor glycemic control [29] . In other research, increased levels of blood glucose levels at the initial assessment were linked to more hospitalization, more in-hospital morbidity, and mortality [30] .…”

Section: Mechanisms Linking Obesity To Ncovid-19mentioning

confidence: 99%

The risk factor for instability metabolic health and severity

Al-Koofee

Omara

Abulrazzaq

et al. 2022

Materials Today: Proceedings

View full text Add to dashboard Cite

Association of glycosylated hemoglobin and outcomes in patients with COVID-19 and pre-existing type 2 diabetes

Cited by 4 publications

References 22 publications

Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis

Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis

Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19

The risk factor for instability metabolic health and severity

Contact Info

Product

Resources

About